Janux Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-11.5M | $-12.5M | $971.0K | $4.0M |
| Jun 2022 | $-6.1M | $-7.0M | $898.0K | $4.4M |
| Sep 2022 | $-13.4M | $-15.9M | $2.5M | $4.6M |
| Mar 2023 | $-13.9M | $-14.2M | $285.0K | $5.5M |
| Jun 2023 | $-15.1M | $-15.6M | $580.0K | $5.5M |
| Sep 2023 | $-11.7M | $-12.2M | $470.0K | $4.5M |
| Mar 2024 | $-14.8M | $-15.0M | $197.0K | $5.6M |
| Jun 2024 | $-10.0M | $-10.1M | $95.0K | $5.8M |
| Sep 2024 | $-2.2M | $-2.3M | $25.0K | $15.4M |
| Mar 2025 | $-17.0M | $-17.4M | $371.0K | $10.7M |
| Jun 2025 | $-23.8M | $-24.3M | $473.0K | $11.0M |
| Sep 2025 | $-12.9M | $-12.9M | $93.0K | $9.0M |
| Mar 2026 | $-12.3M | $-12.6M | $273.0K | $9.3M |
| Jun 2026 | $12.5M | $12.3M | $202.0K | $9.1M |